OpGen's Subsidiary Curetis and FIND Extend R&D Collaboration Agreement; Related Payments Of Up To ~$0.6 Million Will Bring Total Collaboration Commitment To Date To ~$1.5M
Portfolio Pulse from Happy Mohamed
OpGen, Inc. (NASDAQ:OPGN) has announced that its subsidiary, Curetis GmbH, has extended its research and development (R&D) collaboration agreement with FIND. The extension includes payments of up to $0.6 million, bringing the total collaboration commitment to approximately $1.5 million. The collaboration focuses on the development of an antimicrobial resistance (AMR) cartridge from blood culture for low- and middle-income countries (LMICs). The development phase is expected to last about ten months.
August 04, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
OpGen's extended collaboration with FIND could potentially boost its reputation and financial performance in the long run. The development of the AMR cartridge could open new markets in LMICs.
The extended collaboration with FIND could potentially lead to the development of a product that is needed in LMICs. This could open new markets for OpGen and increase its revenues. The successful completion of the project could also enhance OpGen's reputation in the industry.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100